These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 9779838)
1. Circulating levels of interleukin 10 and other cytokines in rheumatoid arthritis treated with cyclosporin A or combination therapy. Ferraccioli G; Falleti E; De Vita S; Di Poi E; Damato R; Casatta L; Salaffi F J Rheumatol; 1998 Oct; 25(10):1874-9. PubMed ID: 9779838 [TBL] [Abstract][Full Text] [Related]
2. Divergent effect of cyclosporine on Th1/Th2 type cytokines in patients with severe, refractory rheumatoid arthritis. Kim WU; Cho ML; Kim SI; Yoo WH; Lee SS; Joo YS; Min JK; Hong YS; Lee SH; Park SH; Cho CS; Kim HY J Rheumatol; 2000 Feb; 27(2):324-31. PubMed ID: 10685792 [TBL] [Abstract][Full Text] [Related]
3. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Julkunen H; Luukkainen R; Vuori K; Paimela L; Blåfield H; Hakala M; Leirisalo-Repo M Arthritis Rheum; 2004 Jan; 50(1):55-62. PubMed ID: 14730599 [TBL] [Abstract][Full Text] [Related]
4. Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry. Berner B; Akça D; Jung T; Muller GA; Reuss-Borst MA J Rheumatol; 2000 May; 27(5):1128-35. PubMed ID: 10813277 [TBL] [Abstract][Full Text] [Related]
5. A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis. Hitchon CA; Alex P; Erdile LB; Frank MB; Dozmorov I; Tang Y; Wong K; Centola M; El-Gabalawy HS J Rheumatol; 2004 Dec; 31(12):2336-46. PubMed ID: 15570632 [TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry. Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA; Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444 [TBL] [Abstract][Full Text] [Related]
7. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T; Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945 [TBL] [Abstract][Full Text] [Related]
8. Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: a comparison with younger-onset disease. Chen DY; Hsieh TY; Chen YM; Hsieh CW; Lan JL; Lin FJ Gerontology; 2009; 55(3):250-8. PubMed ID: 18849599 [TBL] [Abstract][Full Text] [Related]
9. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. Malysheva OA; Wahle M; Wagner U; Pierer M; Arnold S; Häntzschel H; Baerwald CG J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314 [TBL] [Abstract][Full Text] [Related]
10. Enhanced concentrations of interleukin 16 are associated with joint destruction in patients with rheumatoid arthritis. Lard LR; Roep BO; Toes RE; Huizinga TW J Rheumatol; 2004 Jan; 31(1):35-9. PubMed ID: 14705216 [TBL] [Abstract][Full Text] [Related]
11. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis]. Gubar' EE; Bochkova AG; Bunchuk NV Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110 [TBL] [Abstract][Full Text] [Related]
12. Elevated concentrations of monocyte derived cytokines in synovial fluid of children with enthesitis related arthritis and polyarticular types of juvenile idiopathic arthritis. Saxena N; Aggarwal A; Misra R J Rheumatol; 2005 Jul; 32(7):1349-53. PubMed ID: 15996076 [TBL] [Abstract][Full Text] [Related]
13. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954 [TBL] [Abstract][Full Text] [Related]
14. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis. Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365 [TBL] [Abstract][Full Text] [Related]
15. Renal morphology after cyclosporin A therapy in rheumatoid arthritis patients. International Kidney Biopsy Registry of Cyclosporin (Sandimmun) in Autoimmune Diseases. Br J Rheumatol; 1993 Mar; 32 Suppl 1():65-71. PubMed ID: 8448642 [TBL] [Abstract][Full Text] [Related]
16. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate. Seitz M; Zwicker M; Villiger PM J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386 [TBL] [Abstract][Full Text] [Related]
17. Urinary epidermal growth factor and interleukin-6 levels in patients with painful bladder syndrome/interstitial cystitis treated with cyclosporine or pentosan polysulfate sodium. Sairanen J; Hotakainen K; Tammela TL; Stenman UH; Ruutu M Urology; 2008 Apr; 71(4):630-3. PubMed ID: 18387391 [TBL] [Abstract][Full Text] [Related]
18. Conversion of patients with rheumatoid arthritis from the conventional to a microemulsion formulation of cyclosporine: a double blind comparison to screen for differences in safety, efficacy, and pharmacokinetics. Anderson IF; Helve T; Hannonen P; Leirisalo-Repo M; Gilboe IM; Nissilä M; Keystone EC; Kraag GR; Bjørneboe O; Chalmers A; Dovland H; Mueller E; Richard F; Whatmough I; Schmidt AG; Kovarik JM J Rheumatol; 1999 Mar; 26(3):556-62. PubMed ID: 10090162 [TBL] [Abstract][Full Text] [Related]